While ovarian cancer has lagged behind other solid tumors in the availability of targeted therapies, there are now multiple treatment options including PARP inhibitors, immunotherapy, and NTRK inhibitors in our therapeutic arsenal. Here, PARP1 is linked to ovarian carcinoma.